Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial

Breast

Volumn 22, Issue 6, 2013, Pages 1060-1065

  Azim, Hatem A ^a   Rothé, Francoise ^a   Aura, Claudia Monica ^b   Bavington, Malcolm ^c   Maetens, Marion ^a   Rouas, Ghizlaine ^a   Gebhart, Geraldine ^a   Gamez, Cristina ^d   Eidtmann, Holger ^e   Baselga, José ^f   Piccart Gebhart, Martine ^a   Ellis, Catherine ^g   Vuylsteke, Peter ^h   Cure, Hervé ⁱ   Domont, Julien ^j   Ferro, Antonella ^k   Toral Peña, Juan Carlos ^l   de Azambuja, Evandro ^a   Sotiriou, Christos ^a   Di Cosimo, Serena ^m   Ignatiadis, Michail ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^d PET Unit of the Instituto de Dianostico por la Imagen (ID)   (Spain)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g GLAXOSMITHKLINE   (United States)

^h Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

ⁱ INSTITUT JEAN GODINOT   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k SANTA CHIARA HOSPITAL   (Italy)

^l Hospital Torrevieja   (Spain)

^m NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Circulating tumor cells; HER2 positive breast cancer; Lapatinib; PCR; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER GRADING; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE NEU; ONCOLOGICAL PARAMETERS; PATHOLOGICAL COMPLETE RESPONSE; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

CIRCULATING TUMOR CELLS; HER2-POSITIVE BREAST CANCER; LAPATINIB; PCR; TRASTUZUMAB;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOPLASTIC CELLS, CIRCULATING; PACLITAXEL; QUINAZOLINES; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 84887201080     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.08.014     Document Type: Article

References (36)

1. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
2. Ignatiadis M., Desmedt C., Sotiriou C., de Azambuja E., Piccart M. HER-2 as a target for breast cancer therapy. Clin Cancer Res 2009, 15(6):1848-1852.
3. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl J Med 2005, 353(16):1659-1672.
4. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEngl J Med 2005, 353(16):1673-1684.
5. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEngl J Med 2011, 365(14):1273-1283.
6. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344(11):783-792.
7. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. NEngl J Med 2006, 355(26):2733-2743.
8. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012, 366(2):109-119.
9. Saini K.S., Azim H.A., Metzger-Filho O., Loi S., Sotiriou C., de Azambuja E., et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast 2011, 20(Suppl.3):S20-S27.
10. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379(9816):633-640.
11. Gianni L., Pienkowski T., Im Y.H., Roman L., Tseng L.M., Liu M.C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13(1):25-32.
12. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8(5):329-340.
13. Ignatiadis M., Reinholz M. Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res 2011, 13(5):222.
14. Alix-Panabieres C., Schwarzenbach H., Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012, 63:199-215.
15. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. NEngl J Med 2004, 351(8):781-791.
16. De Giorgi U., Valero V., Rohren E., Dawood S., Ueno N.T., Miller M.C., et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. JClin Oncol 2009, 27(20):3303-3311.
17. Pierga J.Y., Hajage D., Bachelot T., Delaloge S., Brain E., Campone M., et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012, 23(3):618-624.
18. Lucci A., Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13(7):688-695.
19. Rack B., Andergassen U., Janni W., Neugebauer J. CTCs in primary breast cancer (I). Recent Results Cancer Res 2012, 195:179-185.
20. Franken B., Degroot M.R., Mastboom W.J., Vermes I., Vanderpalen J., Tibbe A.G., et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 2012, 14(5):R133.
21. Bidard F.C., Mathiot C., Delaloge S., Brain E., Giachetti S., de Cremoux P., et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010, 21(4):729-733.
22. Riethdorf S., Muller V., Zhang L., Rau T., Loibl S., Komor M., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16(9):2634-2645.
23. Pierga J.Y., Petit T., Delozier T., Ferrero J.M., Campone M., Gligorov J., et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012, 13(4):375-384.
24. Ignatiadis M., Rothe F., Chaboteaux C., Durbecq V., Rouas G., Criscitiello C., et al. HER2-positive circulating tumor cells in breast cancer. PLoS One 2011, 6(1):e15624.
25. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004, 101(25):9393-9398.
26. Fehm T., Muller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010, 124(2):403-412.
27. Pestrin M., Bessi S., Puglisi F., Minisini A.M., Masci G., Battelli N., et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 2012, 134(1):283-289.
28. Hayes D.F., Walker T.M., Singh B., Vitetta E.S., Uhr J.W., Gross S., et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002, 21(5):1111-1117.
29. Wulfing P., Borchard J., Buerger H., Heidl S., Zanker K.S., Kiesel L., et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006, 12(6):1715-1720.
30. Lianidou E.S., Mavroudis D., Georgoulias V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer 2013, 108(12):2426-2432.
31. Ithimakin S., Day K.C., Malik F., Zen Q., Dawsey S.J., Bersano-Begey T.F., et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 2013, 73(5):1635-1646.
32. Georgoulias V., Bozionelou V., Agelaki S., Perraki M., Apostolaki S., Kallergi G., et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol Off J Eur Soc Med Oncol/ESMO 2012, 23(7):1744-1750.
33. Jiang Y., Palma J.F., Agus D.B., Wang Y., Gross M.E. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010, 56(9):1492-1495.
34. Attard G., Swennenhuis J.F., Olmos D., Reid A.H., Vickers E., A'Hern R., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69(7):2912-2918.
35. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. Afunctional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402.
36. Heitzer E., Auer M., Gasch C., Pichler M., Ulz P., Hoffmann E.M., et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013, 73(10):2965-2975.